WHO Classification of Tumours of Soft Tissue and Bone, 2013. ,
Management of desmoid tumours: a nationwide survey of labelled reference centre networks in France, Eur J Cancer, vol.58, pp.90-96, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01812682
Desmoid tumors -clinical features and treatment options for advanced disease, Oncologist, vol.16, pp.682-693, 2011. ,
on behalf of the Desmoid Working Group. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients' and professionals' expertise -a Sarcoma Patients EuroNet (SPAEN) and European Organisation For Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) initiative, Eur J Cancer, vol.51, pp.127-136, 2015. ,
b-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis, Histopathology, vol.62, pp.294-304, 2013. ,
CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics, Mod Pathol, vol.25, pp.1551-1558, 2012. ,
ECCO essential requirements for quality cancer care: soft tissue sarcoma in adults and bone sarcoma. A critical review, Crit Rev Oncol Hematol, vol.110, pp.94-105, 2017. ,
Surgical resection margins in desmoid-type fibromatosis: a critical reassessment, Am J Surg Pathol, vol.38, pp.1707-1714, 2014. ,
CTNNB1 genotyping and APC screening in pediatric desmoid tumors: a proposed algorithm, Pediatr. Dev Pathol, vol.15, pp.361-367, 2012. ,
0 Difficult to diagnose 0 desmoid tumours: a potential role for CTNNB1 mutational analysis, Histopathology, vol.59, pp.336-340, 2011. ,
Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis, Genes Chromosomes Cancer, vol.54, pp.606-615, 2015. ,
Specific mutations in the betacatenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors, Am J Pathol, vol.173, pp.1518-1527, 2008. ,
High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management, Br J Cancer, vol.102, pp.1032-1036, 2010. ,
CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study, Cancer, vol.119, pp.3696-3702, 2013. ,
Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis, Ann Surg Oncol, vol.22, pp.1464-1470, 2015. ,
Correlation of CTNNB1 mutation status with progression arrest rate in RECIST progressive desmoidtype fibromatosis treated with imatinib: translational research results from a phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01), Ann Surg Oncol, vol.23, pp.1924-1927, 2016. ,
Desmoid-type fibromatosis, Clin Radiol, vol.70, pp.1038-1045, 2015. ,
Soft-tissue masses in the abdominal wall, Clin Radiol, vol.69, pp.422-431, 2014. ,
Aggressive fibromatosis: MRI features with pathologic correlation, AJR Am J Roentgenol, vol.186, pp.247-254, 2006. ,
MR imaging of extraabdominal desmoids: differentiation from other neoplasms, AJR Am J Roentgenol, vol.158, pp.581-585, 1992. ,
MR appearances of desmoid tumors in familial adenomatous polyposis, AJR Am J Roentgenol, vol.169, pp.465-472, 1997. ,
Can the MRI signal of aggressive fibromatosis be used to predict its behaviour?, Eur J Radiol, vol.69, pp.222-229, 2009. ,
Imaging features of superficial and deep fibromatoses in the adult population, Sarcoma, vol.2012, p.215810, 2012. ,
Soft-tissue masses: histologic basis for decreased signal (short T2) on T2-weighted MR images, AJR Am J Roentgenol, vol.148, pp.1247-1250, 1987. ,
Activity of sorafenib against desmoid tumor / deep fibromatosis, Clin Cancer Res, vol.17, pp.4082-4090, 2011. ,
Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience, Clin Sarcoma Res, vol.2, p.5, 2015. ,
Pathologic and MR imaging features of benign fibrous soft-tissue tumors in adults, Radiographics, vol.27, pp.173-187, 2007. ,
Desmoid-type fibromatosis in the head and neck: CT and MR imaging characteristics, Neuroradiology, vol.55, pp.351-359, 2013. ,
New response evaluation criteria in solid tumors: re-vised RECIST guideline (version 1.1), Eur J Cancer, vol.45, pp.228-247, 2009. ,
From the archives of the AFIP: musculoskeletal fibromatoses-radiologic-pathologic correlation, Radiographics, vol.29, pp.2143-2173, 2009. ,
Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib, Biomed Res Int, p.389672, 2013. ,
The enigma of desmoid tumors, Ann Surg, vol.229, pp.866-872, 1999. ,
Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients, Eur J Surg Oncol, vol.34, pp.462-468, 2008. ,
Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment, Ann Surg Oncol, vol.16, pp.2587-2593, 2009. ,
Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors, J Bone Joint Surg Am, vol.96, pp.631-638, 2014. ,
Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients, Eur J Cancer, vol.51, pp.186-192, 2015. ,
Spontaneous regression of primary abdominal wall desmoids: more common than previously thought, Ann Surg Oncol, vol.20, pp.4096-4102, 2013. ,
Toward a new strategy in desmoid of the breast?, Eur J Surg Oncol, vol.41, pp.571-576, 2015. ,
Toward observation as first-line management in abdominal desmoid tumors, Ann Surg Oncol, vol.23, pp.2212-2219, 2016. ,
Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation, J Clin Oncol, vol.29, pp.3553-3558, 2011. ,
A prognostic nomogram for prediction of recurrence in desmoid fibromatosis, Ann Surg, vol.258, pp.347-353, 2013. ,
Tailored betacatenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention, BMC Cancer, vol.16, p.686, 2016. ,
Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk, Ann Surg, vol.259, pp.973-978, 2014. ,
Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoidtype fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient, Ann Surg Oncol, vol.16, pp.3350-3357, 2009. ,
Isolated limb perfusion using tumour necrosis factor a and melphalan in patients with advanced aggressive fibromatosis, Br J Surg, vol.101, pp.1674-1680, 2014. ,
Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors, Skeletal Radiol, vol.39, pp.175-182, 2010. ,
Percutaneous cryoablation of extraabdominal desmoid tumors: a 10-year experience, AJR Am J Roentgenol, vol.207, pp.190-195, 2016. ,
, Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.25, issue.3, pp.102-112, 2014.
Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis-an EORTC STBSG and ROG study (EORTC 62991-22998), Ann Oncol, vol.24, pp.2672-2676, 2013. ,
Radiotherapy is effective for desmoid tumors (aggressive fibromatosis)-long-term results of a German multicenter study, Oncol Res Treat, vol.37, pp.255-260, 2014. ,
Innovative radiotherapy of sarcoma: proton beam radiation, Eur J Cancer, vol.62, pp.112-123, 2016. ,
Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis, Br J Surg, vol.104, pp.347-357, 2017. ,
Local control of extraabdominal desmoid tumors: systematic review and meta-analysis, Rare Tumors, vol.5, p.2, 2013. ,
A systematic review of active treatment options in patients with desmoid tumours, Curr Oncol, vol.21, pp.613-629, 2014. ,
Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles, Cancer, vol.88, pp.1517-1523, 2000. ,
The pharmacological treatment of aggressive fibromatosis: a systematic review, Ann Oncol, vol.14, pp.181-190, 2003. ,
Optimal therapy for desmoid tumors: current options and challenges for the future, Expert Rev Anticancer Ther, vol.15, pp.1443-1458, 2015. ,
Clinical Activity of the c-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis), J Clin Oncol, vol.35, issue.14, pp.1561-1569, 2017. ,
Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis, Eur J Cancer, vol.51, pp.2800-2807, 2015. ,
Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients, Fam Cancer, vol.15, pp.31-40, 2016. ,
Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a children's oncology group (COG) phase II study, Pediatr Blood Cancer, vol.60, pp.1108-1112, 2013. ,
Aggressive fibromatosis response to tamoxifen: MRI features with symptomatic correlation-the Royal Marsden experience, CTOS Annual Meeting, 2016. ,
Vinblastine and methotrexate for desmoid fibromatosis in children: results of a pediatric oncology group phase II trial, J Clin Oncol, vol.25, pp.501-506, 2007. ,
Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG), Ann Oncol, vol.23, pp.182-186, 2012. ,
Efficacy of oral vinorelbine in advanced/progressive desmoid tumours: an updated retrospective study in 50 patients, J Clin Oncol, vol.34, 2016. ,
Long-term efficacy of methotrexate plus vinblastine / vinorelbine in large series of patients affected by desmoid-type fibromatosis, Cancer J, vol.23, pp.86-91, 2017. ,
Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis, Eur J Cancer, vol.45, pp.2930-2934, 2009. ,
Pegylated liposomal doxorubicin (PLD) as an active treatment option for desmoid tumor (DT) patients, J Clin Oncol, vol.34, 2016. ,
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumour), J Clin Oncol, vol.24, pp.1195-1203, 2006. ,
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up, Ann Oncol, vol.22, pp.452-457, 2011. ,
Phase II study evaluating imatinib to induce progression arrest in RECIST progressive desmoid tumors not amenable to surgical resection with R0 intent or accompanied by unacceptable function loss-a study of the German Interdisciplinary Sarcoma Group (GISG), Ann Oncol, vol.25, p.494, 2014. ,
Imatinib induces sustained progression arrest in RECIST progressive desmoid tumors-final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG), Eur J Cancer, vol.76, pp.60-67, 2017. ,
Efficacy of sorafenib in patients with desmoid-type fibromatosis, J Clin Oncol, vol.34, 2016. ,
Pazopanib, a promising option in the landscape of treatment for aggressive fibromatosis, Anticancer Drugs, vol.28, pp.421-426, 2017. ,
Extremity and trunk desmoid tumors: a multifactorial analysis of outcome, Cancer, vol.86, pp.2045-2052, 1999. ,
Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution, J Clin Oncol, vol.21, pp.1390-1397, 2003. ,
Optimizing treatment of desmoid tumors, J Clin Oncol, vol.25, pp.1785-1791, 2007. ,
Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution, J Surg Oncol, vol.100, pp.563-569, 2009. ,
Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series, Ann Surg Oncol, vol.19, pp.4028-4035, 2012. ,
Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis, Br J Surg, vol.100, pp.1214-1219, 2013. ,
b-Catenin mutation status and outcomes in sporadic desmoid tumors, Oncologist, vol.18, pp.1043-1049, 2013. ,